OP \$315.00 393321

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM346757

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	Trademark Release and Reassignment (Reel:5475/Frame:0733)	

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Barclays Bank PLC, as Collateral Agent		06/30/2015	Public Limited Company: UNITED STATES

RECEIVING PARTY DATA

Name:	Impax Laboratories, Inc., as Grantor
Street Address:	30831 Huntwood Avenue
City:	Hayward
State/Country:	CALIFORNIA
Postal Code:	94544
Entity Type:	CORPORATION: DELAWARE
Name:	CorePharma, L.L.C., a New Jersey Limited Liability Company
Street Address:	215 Wood Avenue
City:	Middlesex
State/Country:	NEW JERSEY
Postal Code:	08846
Entity Type:	LIMITED LIABILITY COMPANY: NEW JERSEY
Name:	Amedra Pharmaceuticals, LLC, a Delaware Limited Liability Company
Street Address:	2 Walnut Grove Drive, Suite 190
City:	Horsham
State/Country:	PENNSYLVANIA
Postal Code:	19044
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE
Name:	Lineage Therapeutics Inc., a Delaware Corporation
Street Address:	2 Walnut Grove Drive, Suite 190
City:	Horsham
State/Country:	PENNSYLVANIA
Postal Code:	19044
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 12

Property Type	Number	Word Mark
Registration Number:	3933211	GLOBAL
		IRADEWARK

900329875 REEL: 005568 FRAME: 0610

Property Type	Number	Word Mark
Registration Number:	3778453	ELADUR
Registration Number:	3849981	COREPHARMA
Registration Number:	3930148	ISODITRATE
Registration Number:	4013212	AMEDRA
Registration Number:	1177791	DEXEDRINE
Registration Number:	3797506	ADRENACLICK
Registration Number:	3101978	TWINJECT
Registration Number:	3449047	TWINJECT AUTO-INJECTOR
Registration Number:	2992781	TWINJECT
Registration Number:	4503141	LINEAGE THERAPEUTICS
Registration Number:	4503142	LINEAGE THERAPEUTICS

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: marina.kelly@thomsonreuters.com

Correspondent Name: Ken Tan, Legal Assistant

Address Line 1: 80 Pine Street

Address Line 2: c/o Cahill Gordon & Reindel LLP
Address Line 4: New York, NEW YORK 10005

NAME OF SUBMITTER: Ken Tan, Legal Assistant		
SIGNATURE:	/Marina Kelly, Thomson Reuters/	
DATE SIGNED:	07/02/2015	

Total Attachments: 5

source=4 Trademark Release#page1.tif

source=4 Trademark Release#page2.tif

source=4 Trademark Release#page3.tif

source=4 Trademark Release#page4.tif

source=4 Trademark Release#page5.tif

Form PTO-1594 (Rev. 12-11)
OMB Collection 0651-0027 (exp. 04/30/2015)

TRADEMARKS ONLY

To the Director of the U.S. Patent and Trademark Office: Please	se record the attached documents or the new address(es) below.
Name of conveying party(ies): Barclay Bank PLC, as Collateral Agent	2. Name and address of receiving party(ies) Additional names, addresses, or citizenship attached? No Name: Impax Laboratories, Inc., as Grantor
Individual(s) Association Partnership Limited Partnership Corporation- State: ✓ Other Public Limited Company Citizenship (see guidelines) USA Additional names of conveying parties attached? Yes ∑ No 3. Nature of conveyance/Execution Date(s): Execution Date(s) June 30, 2015 Assignment Merger Security Agreement Change of Name Trademark Release and Reassignment (Reel:5475 / Other Frame:0733)	Street Address: 30831 Huntwood Avenue City: Hayward State: California Country: USA Zip: 94544 Individual(s) Citizenship Association Citizenship Partnership Citizenship Limited Partnership Citizenship Corporation Citizenship USA Delaware Other Citizenship If assignee is not domiciled in the United States, a domestic representative designation is attached: Yes No (Designations must be a separate document from assignment)
4. Application number(s) or registration number(s) and A. Trademark Application No.(s) See Schedule 1 C. Identification or Description of Trademark(s) (and Filing)	B. Trademark Registration No.(s) Additional sheet(s) attached? Yes No
5. Name & address of party to whom correspondence concerning document should be mailed: Name: Ken Tan, Legal Assistant	6. Total number of applications and registrations involved:
Internal Address:	7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$
Street Address: c/o Cahill Gordon & Reindel LLP 80 Pine Street	Authorized to be charged to deposit account Enclosed
City: New York	8. Payment Information:
State: New York Zip: 10005	
Phone Number: (212) 701-3804	
Docket Number: 08380.0595	Deposit Account Number
Email Address: KTan@cahill.com	Authorized User Name
9. Signature:	07/01/2015
√ ∫ Signature	Date
Ken Tan	Total number of pages including cover sheet, attachments, and document: 5
Name of Person Signing	was a second of the second of

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Branch, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

Addendum to Cover Page of Trademarks Form Cover Sheet

2. Name of receiving party(ies)

CorePharma, L.L.C., a New Jersey Limited Liability Company Citizenship – USA – NJ 215 Wood Avenue Middlesex, NJ 08846

Amedra Pharmaceuticals, LLC, a Delaware Limited Liability Company Citizenship – USA – DE 2 Walnut Grove Drive, Suite 190 Horsham, PA 19044

Lineage Therapeutics Inc., a Delaware Corporation Citizenship – USA – DE 2 Walnut Grove Drive, Suite 190 Horsham, PA 19044

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Release"), dated as of June 30, 2015 (the "Effective Date"), is made by Barclays Bank PLC, in its capacity as Collateral Agent (the "Collateral Agent"), in favor of the grantor party identified on the signature page hereto (the "Grantor").

WHEREAS, pursuant to that certain Security Agreement, dated as of March 9, 2015, by and among the Collateral Agent, the Grantor and certain other parties thereto (as amended, amended and restated, or otherwise modified from time to time, the "Security Agreement"), the Grantor granted to the Collateral Agent, in its capacity as Collateral Agent, a security interest in and to certain collateral;

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered a Trademark Security Agreement, dated as of March 9, 2015 (the "<u>Trademark Security Agreement</u>"), for recordal with the United States Patent and Trademark Office;

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on March 11, 2015 at Reel/Frame 5475/0733;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees as follows:

- 1. <u>Defined Terms</u>. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the Trademark Security Agreement, as applicable.
- 2. Release. The Collateral Agent, without representation or warranty of any kind, hereby releases, discharges, terminates and cancels all of its security interest in and to Trademark Collateral, including the trademark registrations and applications set forth on Schedule 1 attached hereto, arising under the Security Agreement and the Trademark Security Agreement. If and to the extent that the Collateral Agent has acquired any right, title or interest in and to the Trademark Collateral under the Trademark Security Agreement, the Collateral Agent, without representation or warranty of any kind, hereby retransfers, reconveys and reassigns such right, title or interest to the Grantor.
- 3. <u>Termination</u>. The Collateral Agent, without representation or warranty of any kind, terminates and cancels the Trademark Security Agreement.
- 4. <u>Further Assurances</u>. The Collateral Agent agrees to take all further actions, and provide to the Grantor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantor, at the Grantor's sole cost and expense, to more fully and effectively effectuate the purposes of this Release.
- 5. <u>Governing Law</u>. This Release shall be governed exclusively under the laws of the State of New York, without regard to conflicts of law or choice of law principles.

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

BARCLAYS BANK PLC, acting in its capacity as Collateral Agent for the Secured Parties

By:

Name: Craig J. Malloy

Title: Director

GRANTORS:

IMPAX LABORATORIES, INC.

LINEAGE THERAPEUTICS INC.

COREPHARMA, L.L.C.

AMEDRA PHARMACEUTICALS LLC

SCHEDULE 1

Registrations:

RECORDED: 07/02/2015

Owner	Trademark	Registration Number / Registration Date
Impax Laboratories, Inc.	GLOBAL (w/ logo)	US Reg. No. 3,933,211 March 22, 2011
Impax Laboratories, Inc.	ELADUR	US Reg. No. 3,778,453 April 20, 2010
CorePharma, L.L.C.	Corepharma	US Reg. No. 3,849,981 September 21, 2010
CorePharma, L.L.C.	Isoditrate	US Reg. No. 3,930,148 March 8, 2011
Amedra Pharmaceuticals LLC	Amedra	US Reg. No. 4,013,212 August 16, 2011
Amedra Pharmaceuticals LLC	Dexedrine	US Reg. No. 1,177,791 November 17, 1981
Lineage Therapeutics Inc.	Adrenaclick	US Reg. No. 3,797,506 June 1, 2010
Lineage Therapeutics Inc.	Twinject	US Reg. No. 3,101,978 June 6, 2006
Lineage Therapeutics Inc.	Twinject Auto-injector	US Reg. No. 3,449,047 June 17, 2008
Lineage Therapeutics Inc.	Twinject	US Reg. No. 2,992,781 September 6, 2005
Lineage Therapeutics Inc.	Lineage Therapeutics	US Reg. No. 4,503,141 March 25, 2014
Lineage Therapeutics Inc.	Lineage Therapeutics	US Reg. No. 4,503,142 March 25, 2014